
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Auckland, New Zealand - Intradermal injection of a purified cell wall component from heat-killed Mycobacterium vaccae may one day be used to treat children with severe atopic dermatitis, if a clinical program carried out by a New Zealand company continues to be successful.






